Application of stable silicic acid aqueous solution in preparation of product for treating war wound infection

Abstract

The invention relates to the technical field of biological medicine, in particular to application of a stable silicic acid aqueous solution in preparation of a product for treating war wound infection, and the mass concentration of the stable silicic acid aqueous solution is 0.5%-2%. The product taking the stable silicic acid aqueous solution as the active ingredient can be used for treating war wound infection or cryptococcus gattii infection, can resist cryptococcus gattii infection at the mass concentration of 0.5-2%, and has the effect of resisting war wound infection, and meanwhile, the stable silicic acid aqueous solution is low in raw material cost, environment-friendly, safe and suitable for industrial production. The compound can be used as a substitute medicine of a traditional medicine miconazole with a good curative effect.

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to the application of a stable silicic acid aqueous solution in the preparation of a product for treating war wound infection. Background Art

[0002] Cryptococcus gattii is an important invasive pathogenic fungus that is widely distributed in the environment, mainly in bird feces and soil, with a high risk of airborne transmission. Cryptococcus gattii can enter the lungs through the respiratory system, causing fatal cryptococcal pneumonia and cryptococcal meningitis (with a mortality rate of up to 30%-50%), and can also cause skin infections through wounds and further cause fatal deep infections, such as lung infections and brain infections.

[0003] For deep infections (lung and brain infections) caused by Cryptococcus gothi, only three drugs, amphotericin B, fluconazole and flucytosine, are currently available for the treatment of this type of deep infection. Amphotericin B is the only bactericidal drug among them, and it has strong toxic side effects and cannot be used for long-term treatment of cryptococcal infections. The entire treatment process includes three stages: induction therapy, consolidation therapy and maintenance therapy. The treatment cycle is long, the treatment cost is high, and treatment failure or recurrent infection occurs frequently.

[0004] Battle wound infection is one of the main threats faced by battlefield casualties, with an infection rate as high as 20%-30%, and even up to 50% in the intensive care unit (ICU). Battle wound infection can not only lead to sepsis and multiple organ failure, causing a mortality rate of up to 20%-40%, but also significantly prolong recovery time and increase amputation and reoperation rates. In addition, the proportion of multidrug-resistant bacteria (bacteria and fungi) in battle wound infection is as high as 44.6%-63%, which further increases the difficulty of treatment. Infection caused by Cryptococcus gothiola is a common and typical infection of battle wound infection.

[0005] Miconazole is currently the only treatment for skin infections caused by combat injuries or wounds. However, the treatment cycle of miconazole is long and the effect is average. It often needs to be combined with debridement to completely cure cryptococcal infection. Summary of the invention

[0006] The purpose of the present invention is to address the problems existing in drugs for cryptococcal infection and propose an alternative drug, which utilizes a stable silicic acid aqueous solution to prepare a product for treating war wound infection to obtain better therapeutic effects.

[0007] To achieve the above-mentioned object, the present invention provides an application of a stable silicic acid aqueous solution in the preparation of a product for treating war wound infections, wherein the mass concentration of the stable silicic acid aqueous solution is 0.5% to 2%.

[0008] Furthermore, the present invention provides an application of a stable silicic acid aqueous solution in the preparation of a product for treating Cryptococcus gattii infection, wherein the mass concentration of the stable silicic acid aqueous solution is 0.5% to 2%.

[0009] Preferably, when used for external application, the stable silicic acid aqueous solution is dispersed in an ointment base as an active ingredient.

[0010] Furthermore, the present invention provides a product for treating war wound infection or Cryptococcus gattii infection, wherein the active ingredient of the product is a stable silicic acid aqueous solution with a mass concentration of 0.5% to 2%, and the product is a medical device or a drug.

[0011] Based on the above technical solution, the advantages of the present invention are:

[0012] The stable silicic acid aqueous solution of the present invention is used as an active ingredient, and can resist Cryptococcus gattii infection at a mass concentration of 0.5% to 2%, has clinical application value in resisting pathogenic fungi, and has the effect of resisting war wound infection. At the same time, the raw material cost of the stable silicic acid aqueous solution is low, and it is environmentally friendly and safe, and can be used as a substitute for the traditional drug miconazole with good therapeutic effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] The drawings described herein are used to provide a further understanding of the present invention and constitute a part of this application. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. In the drawings:

[0014] Figure 1 , A is a photo of the culture of mice infected with Cryptococcus gattii treated with the control group (untreated), miconazole, and metasilicic acid aqueous solution to evaluate the bacterial load of Cryptococcus gattii at the infection site;

[0015] Figure 1 , B is the evaluation results of the bacterial load of Cryptococcus gattii at the infection site of mice infected with Cryptococcus gattii treated with the control group (untreated), miconazole, and metasilicic acid aqueous solution;

[0016] Figure 2 Phenotypic changes of mice infected with Cryptococcus gattii after being treated with the control group (untreated), miconazole, and metasilicic acid aqueous solution. DETAILED DESCRIPTION

[0017] The technical solution of the present invention is further described in detail below through the accompanying drawings and embodiments.

[0018] The present invention provides an application of a stable silicic acid aqueous solution in the preparation of a product for treating war wound infection, wherein the mass concentration of the stable silicic acid aqueous solution is 0.5% to 2%.

[0019] It should be noted that the stable silicic acid aqueous solution in the present invention is a stable stable silicic acid aqueous solution, wherein the stable silicic acid aqueous solution refers to a solution in a stable state without polymerization, and its main components include monosilicic acid (H4SiO4), metasilicic acid (H2SiO3) and hydrogen silicate (HSiO3 - ), the mass concentration of 0.5% to 2% in the present invention means that the total concentration of the main components is 0.5% to 2%.

[0020] In order to illustrate the application effect of the stabilized silicic acid aqueous solution in the preparation of a product for treating war wound infection, this example uses BALB / c Nude mice as infection subjects to simulate a human war wound infection model as an example for illustration:

[0021] (1) Model establishment

[0022] Battle wound infection model: BALB / c Nude mice were used as the infection subjects, and a 4 mm mouse skin punch was used to punch holes on the mouse skin surface to simulate battle wounds (see the specific location for details). Figure 2 The mouse image is shown in Figure 1). The pathogen Cryptococcus gattii R265-Gattii Cryptococcus (a malignant fungus) was selected for infection of the skin punch area. The infection dose of Gattii Cryptococcus was 100 μL with a concentration of 10 9 cells / mL of yeast suspension is inoculated into the wound to infect the host, and treatment begins after colonization.

[0023] (2) Experimental groups and treatment plans

[0024] Three groups were set up for each fungal infection experiment: control group, drug treatment group and metasilicic acid aqueous solution treatment group. The control group used sterile water, the drug group used antifungal drug miconazole with a concentration of 100 μg / mL, and the metasilicic acid aqueous solution group used a stable silicic acid aqueous solution with a mass concentration of 1%. A 15 mL nozzle was used to spray the infected area of ​​the mice 10 times a day, twice a day, for 7 consecutive days, and the treatment effect was observed and the bacterial load and other phenotypes were measured to conduct a comprehensive evaluation of the antifungal effect.

[0025] (3) Observation indicators

[0026] a. Observe the wound changes in the infected area of ​​the mice after treatment and monitor the diet and mental state of the mice;

[0027] b. The infected area of ​​the mouse was dissected and removed, and after homogenization and filtration, the bacterial load was tested and statistically analyzed.

[0028] (4) Effect of metasilicic acid aqueous solution on the clearance of Cryptococcus gattii infection

[0029] Compared with the untreated control group of infected mice, the load of Cryptococcus gattii in the infected area of ​​mice was significantly reduced (detected 7 days after treatment) after one week of continuous treatment with metasilicic acid aqueous solution, which was sprayed 10 times a day with a 15 mL spray head on the infected area of ​​mice (8 hours interval between the two times) (see Figure 1 A, B); At the same time, the drug treatment group took miconazole at a concentration of 100 μg / mL, and also used a 15 mL nozzle to spray 10 times a day on the infected area of ​​the mice, twice a day. Compared with the untreated control group infected mice, the load of Cryptococcus gattii in the infected area was significantly reduced (see Figure 1 A, B).

[0030] In addition, compared with the untreated control group infected mice, the infection symptoms of mice treated with metasilicic acid aqueous solution for 7 days were significantly suppressed and showed an improvement trend (see Figure 2 ); At the same time, after 7 days of treatment with 100 μg / mL miconazole, the infection symptoms of the infected part of the mice in the drug treatment group were significantly suppressed compared with the untreated control group infected mice, showing a trend of improvement (see Figure 2 ).

[0031] (5) Conclusion

[0032] A stable silicic acid aqueous solution was used to spray the infected area of ​​mice infected with Cryptococcus gattii 10 times a day with a 15 mL spray nozzle, twice a day (with an interval of 8 hours between the two times). After one week of treatment, the fungal load in the infection site of mice infected with Cryptococcus gattii decreased significantly, and the infection symptoms in the infection site were significantly suppressed, showing a trend of improvement.

[0033] Since Cryptococcus gattii infection is often a typical manifestation of war wound infection, the stable silicic acid aqueous solution of the present invention can also be used in the preparation of products for treating war wound infection, wherein the mass concentration of the stable silicic acid aqueous solution is 0.5% to 2%. When used for external application, the stable silicic acid aqueous solution is dispersed in the ointment matrix as an active ingredient to obtain a more suitable use method.

[0034] Furthermore, the present invention provides a product for treating war wound infection or Cryptococcus gattii infection, wherein the active ingredient of the product is a stable silicic acid aqueous solution with a mass concentration of 0.5% to 2%, and the product is a medical device or a drug.

[0035] The stable silicic acid aqueous solution of the present invention is used as an active ingredient, and can resist Cryptococcus gattii infection at a mass concentration of 0.5% to 2%, has clinical application value in resisting pathogenic fungi, and has the effect of resisting war wound infection. At the same time, the raw material cost of the stable silicic acid aqueous solution is low, and it is environmentally friendly and safe, and can be used as a substitute for the traditional drug miconazole with good therapeutic effect.

[0036] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, ordinary technicians in the field should understand that the specific implementation methods of the present invention can still be modified or some technical features can be replaced by equivalents without departing from the spirit of the technical solution of the present invention, which should be included in the scope of the technical solution for protection of the present invention.

Claims

1. Application of a stable silicic acid aqueous solution in the preparation of a product for treating war wound infection, wherein: The mass concentration of the stable silicic acid aqueous solution is 0.5% to 2%.

2. Use of a stable silicic acid aqueous solution in the preparation of a product for treating Cryptococcus gattii infection, wherein: The mass concentration of the stable silicic acid aqueous solution is 0.5% to 2%.

3. The use according to claim 1 or 2, characterized in that: When used for external application, the stable silicic acid aqueous solution is dispersed in an ointment base as an active ingredient.

4. A product for treating war wound infection or Cryptococcus gattii infection, characterized in that: The active ingredient of the product is a stable silicic acid aqueous solution with a mass concentration of 0.5% to 2%, and the product is a medical device or a drug.

Images